Health Care Professionals News

[From Medscape, Pam Harrison, Nov 6, 2014] The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show. The finding, presented at the HIV Drug Therapy Congress in Glasgow, United Kingdom, supports the use of a lower dose of the drug in combination with tenofovir plus […]

[From International AIDS Society, Mark Mascolini, Nov 13, 2014] Markers of gut epithelial barrier integrity, immune activation, inflammation, and coagulation predicted mortality in a case-control study of a US cohort responding to antiretroviral therapy (ART). Previous research showed that heightened inflammation predicts mortality in HIV-positive people taking ART. Because less is known about the prognostic value

“Kids These Days” Reconsidering our conversation about Generation Me Dr. Glenn Regehr Associate Director of Research, Centre for Health Education Scholarship, UBC Professor, Department of Surgery, UBC Wednesday November 12, 2014, 12:00-1:00PM Hurlburt Auditorium, St. Paul’s Hospital This is a public event. A light lunch will be served.

[From MedicalXpress, Oct 27, 2014] A nationwide study based at Massachusetts General Hospital (MGH) will investigate, for the first time, whether treatment with a statin drug can reduce the elevated risk of cardiovascular disease in individuals infected with the human immunodeficiency virus (HIV). The REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial is

This is an open educational event sponsored by the BC Centre for Excellence in HIV/AIDS and accredited by the College of Family Physicians of Canada. A light breakfast, lunch and refreshments throughout the day will be provided on site. Topics include the following: Antiretroviral Therapy Update HIV-related Comorbidities and Co-infections Addictions and Mental Health The